Metoclopramide G.L. Pharma (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This reduces the signal that initiates vomiting and increases the tone of the upper GI smooth muscle, promoting coordinated peristalsis and faster gastric emptying. It also has weak antagonistic activity at serotonin 5‑HT3 receptors and enhances acetylcholine release, supporting its pro‑kinetic effect.

The dose of Metoclopramide is individualized by the prescribing clinician based on the specific indication, patient age, renal function, and route of administration. Healthcare professionals determine the appropriate amount and frequency, and patients should follow the prescriber’s instructions without deviation.

Safety data for Metoclopramide during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternative to Metoclopramide is the 5‑HT3 receptor antagonist class, such as ondansetron. While ondansetron primarily blocks serotonin receptors and is effective for chemotherapy‑induced nausea, Metoclopramide adds a pro‑kinetic effect by enhancing gastric motility. Choice between them depends on the underlying cause of nausea, patient tolerance, and the risk profile of each agent.

Metoclopramide G.L. Pharma should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperature fluctuations. Do not freeze the solution. Follow any additional handling instructions provided on the label or by the supplier.

Metoclopramide is supplied as an injectable solution for intramuscular (IM) or intravenous (IV) administration. The route, rate of infusion, and duration are determined by the prescribing clinician based on the clinical situation. It is not formulated for oral use in this presentation.

Serious risks include tardive dyskinesia, a potentially irreversible movement disorder, neuroleptic malignant syndrome, severe depression or suicidal thoughts, seizures, anaphylactic reactions, and hyperprolactinemia leading to hormonal disturbances. Patients should be instructed to report any involuntary movements, mood changes, severe skin reactions, or signs of infection promptly.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients, in patients with pheochromocytoma, and in those with a history of severe extrapyramidal reactions or neuroleptic malignant syndrome. Caution is also advised for patients with renal failure, epilepsy, or uncontrolled depression, and it should be avoided in children under 1 year of age.